Promising new combo aims to boost lymphoma treatment without added risk
NCT ID NCT05994235
First seen Apr 10, 2026 · Last updated Jun 14, 2026 · Updated 14 times
Summary
This study tests whether combining two drugs—tazemetostat (a pill) and mosunetuzumab (an injection)—is safe and effective for people with follicular lymphoma who have not yet been treated. The goal is to see if the combination can improve the number of patients whose cancer disappears completely. The study involves 23 adults and uses the immune system to fight the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Weill Cornell Medicine/NewYork-Presbyterian Hospital
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.